Prescription drug · ANDA
Rivastigmine Tartrate NDC 71209-013
Rivastigmine tartrate 3 mg/1 · Capsule · Oral · Cadila Pharmaceuticals Limited
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 71209-013-03 | 71209001303 | 60 CAPSULE in 1 BOTTLE (71209-013-03)Marketed from Feb 11, 2014 | |
| 71209-013-10 | 71209001310 | 500 CAPSULE in 1 BOTTLE (71209-013-10)Marketed from Feb 11, 2014 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Rivastigmine Tartrate
- Generic name (nonproprietary)
- rivastigmine tartrate
- Active ingredients
- Rivastigmine tartrate — 3 mg/1
- Dosage form
- Capsule
- Route
- Oral
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 203844
- Marketing start
- Listing expires
- Other FDA classes
- Cholinesterase Inhibitors (Mechanism)
- Identifiers
- Product ID 71209-013_862f0b42-695e-4170-983d-cfb848967cf3SPL ID 862f0b42-695e-4170-983d-cfb848967cf3SPL set ID e7e641fe-39bd-4681-a430-6dedeb6d6af5RxCUI 312835, 312836, 314214, 314215UNII 9IY2357JPEUPC 0371209012034, 0371209014038, 0371209013031
- Pharmacologic class
- Cholinesterase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N471209001303followed by a unit qualifier and the quantityPackage 71209-0013-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
1 INDICATIONSAND USAGE Rivastigmine tartrate is an acetylcholinesterase inhibitor indicated for treatment of: • Mild-to-moderate dementia of the Alzheimer's type (AD) ( 1.1 ) • Mild-to-moderate dementia associated with Parkinson's disease (PD) ( 1.2 ) 1.1 Alzheimer's Disease Rivastigmine tartrate capsules, USP are indicated for the treatment of mild-to-moderate dementia of the Alzheimer's type (AD). 1.2 Parkinson's Disease Dementia Rivastigmine tartrate capsules, USP are indicated for the treatment of mild-to-moderate dementia associated with Parkinson's disease (PD).
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 203844
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Rivastigmine Tartrate | Rivastigmine tartrate 1.5 mg/1 | CapsuleOral | Cadila Pharmaceuticals Limited | 71209-012 |
| Rivastigmine Tartrate | Rivastigmine tartrate 4.5 mg/1 | CapsuleOral | Cadila Pharmaceuticals Limited | 71209-014 |
| Rivastigmine Tartrate | Rivastigmine tartrate 6 mg/1 | CapsuleOral | Cadila Pharmaceuticals Limited | 71209-015 |
| Rivastigmine Tartrate | Rivastigmine tartrate 1.5 mg/1 | CapsuleOral | Modavar Pharmaceuticals LLC | 72241-011 |
| Rivastigmine Tartrate | Rivastigmine tartrate 4.5 mg/1 | CapsuleOral | Modavar Pharmaceuticals LLC | 72241-013 |
| Rivastigmine Tartrate | Rivastigmine tartrate 3 mg/1 | CapsuleOral | Modavar Pharmaceuticals LLC | 72241-012 |
| Rivastigmine Tartrate | Rivastigmine tartrate 6 mg/1 | CapsuleOral | Modavar Pharmaceuticals LLC | 72241-014 |